Magle Chemoswed Holding AB (MAGLE) AI Stock Analysis

• Market Cap: €396.47M
• Dividend Yield: N/A
• Average Volume (3M): 1.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: 60.52%
• EPS Growth: -179.01%
• Country: SE
• Employees: 147
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 20,649,378
• 10 Day Avg. Volume: 1,291
• 30 Day Avg. Volume: 1,058
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: kr18.50 ▼(-2.63% Downside)

Magle Chemoswed Holding AB's overall stock score is primarily impacted by its financial performance and valuation concerns. The company struggles with profitability and cash flow management, and its technical indicators suggest bearish momentum. The negative P/E ratio further highlights the financial challenges.

Magle Chemoswed Holding AB Business Overview & Revenue Model

Company Description

Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacturing in the areas of pharmaceutical chemistry and pharmaceutical technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); and research, development, and production of products in the areas of wound care and diagnostics with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical devices for applications in the areas of advanced wound care, surgical and diagnostics, and drug delivery comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology; SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures; and EmboCept M, a device for use in the treatment of benign prostatic hyperplasia. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company was founded in 1944 and is headquartered in Malmö, Sweden. Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.

How the Company Makes Money

Magle Chemoswed Holding AB makes money through a diversified revenue model that includes the sale of proprietary products, contract development and manufacturing services, and licensing agreements. The company's key revenue streams are derived from its cutting-edge drug delivery systems, which provide enhanced therapeutic benefits and meet specific client needs. Additionally, Magle Chemoswed partners with pharmaceutical and biotech companies, leveraging its expertise in drug formulation and manufacturing to generate income. Licensing of its proprietary technologies to third parties also contributes to its earnings, allowing the company to capitalize on its innovative solutions in various markets.

Magle Chemoswed Holding AB Financial Statement Overview

Summary

Magle Chemoswed Holding AB faces financial challenges, particularly in profitability and cash flow management. The income statement and cash flow metrics highlight areas of concern, with negative EBIT margin and operating cash flow. The balance sheet shows moderate stability with a manageable debt-to-equity ratio.

Income Statement

Magle Chemoswed Holding AB shows a mixed performance in its income statement. The TTM data indicates a slight revenue growth of 2.3%, but the company is struggling with profitability, as evidenced by a negative EBIT margin of -3.2% and a net loss. Historical data shows fluctuating revenue growth and declining profit margins, suggesting challenges in maintaining consistent profitability.

Balance Sheet

The balance sheet reflects moderate financial stability. The debt-to-equity ratio of 0.59 in the TTM period indicates manageable leverage, although it has increased over time. The return on equity is negative in the TTM period, highlighting profitability issues. However, the equity ratio remains healthy, suggesting a solid capital structure.

Cash Flow

Cash flow analysis reveals significant challenges. The company has negative operating cash flow and free cash flow in the TTM period, indicating cash management issues. Although there was a substantial increase in free cash flow growth, it stems from a low base, and the operating cash flow to net income ratio is negative, reflecting inefficiencies in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	285.59M	236.04M	170.44M	145.68M	132.15M	142.34M
Gross Profit	266.89M	221.55M	152.87M	134.38M	110.83M	111.94M
EBITDA	49.86M	59.21M	31.40M	25.77M	18.14M	14.88M
Net Income	-20.16M	11.94M	12.17M	9.14M	4.28M	1.82M
Balance Sheet
Total Assets	1.04B	1.09B	272.97M	252.86M	237.18M	198.06M
Cash, Cash Equivalents and Short-Term Investments	2.15M	2.72M	7.08M	9.88M	3.98M	6.12M
Total Debt	342.63M	349.63M	60.30M	50.34M	36.46M	44.82M
Total Liabilities	508.92M	531.58M	114.75M	106.09M	98.39M	81.94M
Stockholders Equity	529.23M	560.60M	158.22M	146.77M	138.79M	116.12M
Cash Flow
Free Cash Flow	-10.20M	-27.85M	209.00K	-4.41M	14.21M	-17.95M
Operating Cash Flow	-19.91M	-11.70M	15.33M	12.47M	26.04M	-5.54M
Investing Cash Flow	-7.04M	-9.97M	-20.41M	-21.49M	-34.05M	-15.08M
Financing Cash Flow	25.33M	17.09M	2.52M	14.80M	5.87M	23.45M

Magle Chemoswed Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 19.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MAGLE, the sentiment is Negative. The current price of 19 is below the 20-day moving average (MA) of 19.80, below the 50-day MA of 20.40, and below the 200-day MA of 26.16, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 44.91 is Neutral, neither overbought nor oversold. The STOCH value of 24.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MAGLE.

Magle Chemoswed Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMMU	―	kr389.07M	―	-16.60%	―	―	39.56%
IVACC	―	kr344.90M	―	-26.89%	―	86.56%	49.49%
MAGLE	―	€396.47M	-34.24	-6.09%	―	60.52%	-179.01%
XBRANE	―	€309.08M	2.32	-16.90%	―	4.64%	―
GUARD	―	€463.86M	-2.55	-159.75%	―	―	-20.61%